Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 15, 2006Clinical Cancer ResearchOpen Access

PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

DVDonkena Krishna VanajaVijayanagara Institute of Medical SciencesKBKarla V. BallmanRutgers, The State University of New JerseyBMBruce W. MorlanMayo Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vanaja et al. (2006) studied this question.

synapsesocial.com/papers/6a905d9cf009383eee841fd0https://doi.org/10.1158/1078-0432.ccr-05-2072
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma2004 · 88 citations
  2. 2Gene expression profiling identifies clinically relevant subtypes of prostate cancer2004 · 1,316 citations
  3. 3Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer2005 · 288 citations